MENU
X
  • Home
  • Major needs
  • Science
    • Technology
    • Pipeline
    • Posters and Publications
  • Products
    • Plenity Clinical Data
    • Plenity Site
  • People
    • Leadership team
    • Scientific Advisors
    • Board of Directors
  • Press
  • Investors
  • Careers
Region
Worldwide Site
Gelesis SRL - Italy
X
READ THE ARTICLE

Plenity is an aid for weight management in adults who are overweight or obese and have a body mass index (BMI) of 25 to 40 kg/m , when combined with diet and exercise.

IMPORTANT SAFETY INFORMATION

  • Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity.
  • To avoid impact on the absorption of medications:
    • For all medications that should be taken with food, take them after starting a meal.
    • For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician.
  • The overall incidence of side effects with Plenity was no
    different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence.
  • Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor.

Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

X
READ THE ARTICLE

Plenity is an aid for weight management in adults who are overweight or obese and have a body mass index (BMI) of 25 to 40 kg/m , when combined with diet and exercise.

The physician who wrote the following article is an advisor to Gelesis (the maker of Plenity).

IMPORTANT SAFETY INFORMATION

  • Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity.
  • To avoid impact on the absorption of medications:
    • For all medications that should be taken with food, take them after starting a meal.
    • For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician.
  • The overall incidence of side effects with Plenity was no
    different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence.
  • Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor.

Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

PRESS RELEASES

Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical Models Compared to Prebiotics
November 02, 2022
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity Week
November 01, 2022
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome
August 26, 2022
Gelesis Reports Second Quarter 2022 Results
August 15, 2022
Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
June 21, 2022
Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study
June 05, 2022
Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel
June 04, 2022
Gelesis Reports First Quarter 2022 Results
May 12, 2022
Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes
May 04, 2022
Gelesis’ Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study
May 02, 2022
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
March 24, 2022
Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic
March 20, 2022
Plenity® National Media Campaign Kicking Off Today Challenges Restrictive Dieting Norms
January 31, 2022
Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar
January 13, 2022
Have Your Cake and Eat It Too: Plenity® Creates Edible Dessert Billboard to Challenge Overly Restrictive Dieting Assumptions
December 16, 2021
Gelesis’ FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
December 01, 2021
Gelesis Receives $30 Million Plenity® Order from Ro
November 18, 2021
Nature’s Scientific Reports Features Gelesis’ Novel and Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage
November 18, 2021
Two Senior Scientific Leaders at Gelesis Awarded Top Industry Honors
November 18, 2021
Gelesis, a Consumer-Focused Biotherapeutics Company and the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp.
July 19, 2021
Procter & Gamble Veteran Jane Wildman Joins Gelesis Board of Directors
April 26, 2021
New Survey Finds 71 Million Americans Have Gained Weight Throughout the Pandemic
December 22, 2020
Gelesis Presents Pre-Clinical Data Suggesting Proprietary Hydrogel (GS300 Prototype) Reverses the Damage to the Intestines Induced by a High Fat Diet
November 13, 2020
Gelesis Presents Three Poster Presentations at ObesityWeek® 2020
November 03, 2020
Gelesis to Present New Data at The Obesity Society’s ObesityWeek® and The American Association for the Study of Liver Disease’s The Liver Meeting®
November 02, 2020
Plenity® Efficacy and Safety Data to be Presented at the European and International Congress on Obesity 2020
September 04, 2020
Gelesis Announces Partnership for Commercial Launch of Plenity® in China
June 18, 2020
Gelesis Receives Approval to Market PLENITY™ in Europe as a Weight Loss Treatment
June 02, 2020
Gelesis Named One of the World’s Most Innovative Companies for 2020 by Fast Company
March 10, 2020
Gelesis Announces Partnership with Ro on Commercial Launch of Plenity™
December 17, 2019
Gelesis Secures Over $84 Million in New Capital to Support Commercialization of PLENITY™
December 09, 2019
Pivotal Data Presented at ObesityWeek 2019 Highlight the Therapeutic Benefits of Plenity™ in Adults with Obesity and Underscore its Safety and Efficacy in Lower-BMI Overweight Adults
November 05, 2019
New Plenity™ Pivotal Safety and Efficacy Data to be Presented at ObesityWeek 2019
October 29, 2019
Promising Clinical Data from Pilot Study of Gelesis’ Novel Hydrogel GS500 Prototype for the Potential Treatment of Chronic Constipation Presented at Digestive Disease Week by Researchers from Massachusetts General Hospital and Brigham and Women’s Hospital
May 19, 2019
Gelesis Awarded $10.6 (€9.4) Million Grant to Support Commercial Manufacturing of PLENITY™
April 25, 2019
Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management
April 14, 2019
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Prevents Harmful Effects of a High-Fat Diet
April 11, 2019
Gelesis Presents Expanded Data Showing Impact of Gelesis100 Hydrogel on Patients with Prediabetes, Untreated Diabetes, and Elevated Insulin Resistance
March 25, 2019
Gelesis Presents Preclinical Data Showing Proprietary Hydrogel Restores Gut Barrier Function
March 25, 2019
Gelesis Announces Three Presentations at Annual Endocrine Society Meeting
March 21, 2019
Pivotal Weight Loss Data for Gelesis100 Published in Obesity, Including Predictors of Response
November 13, 2018
Gelesis Announces Presentations of Expanded Pivotal Data at ObesityWeek 2018
November 05, 2018
Harry Leider, Former Chief Medical Officer of Walgreens, joins Gelesis as Chief Medical Officer, and Paul Fonteyne, Chairman and Former CEO of Boehringer Ingelheim USA, joins the Gelesis Board of Directors
June 06, 2018
Gelesis Raises $30 Million to Prepare for Potential Launch of Lead Product
March 01, 2018
Gelesis100 Achieves Significant Weight Loss with Excellent Safety Profile in Pivotal Study
September 25, 2017
Gelesis Announces Last Patient Out in the Pivotal Gelesis100 Weight-Loss Study
July 12, 2017
Gelesis Announces €2.9 Million Award from Italian Ministry of Economic Development
May 03, 2017
Administration of Gelesis200 Increases Fullness and Satiety in People who are Overweight or Have Obesity
September 02, 2016
Gelesis Appoints New Chief Operating Officer
September 02, 2016
Gelesis Announces Positive Safety Data from First-In-Human Study of Second Product Candidate, Gelesis200
May 03, 2016
Gelesis Announces First U.S. Patient Enrolled in Pivotal Gelesis100 Weight-Loss Study
April 26, 2016
Gelesis Closes $31.5 Million Growth Financing
December 18, 2015
Gelesis Expands Ongoing Weight Loss Study to Serve as U.S. Pivotal Trial, Significantly Accelerating Development Timeline
July 27, 2015
Gelesis Presents Additional Data at European Congress on Obesity
May 22, 2015
Gelesis Closes $22M Equity Financing
April 01, 2015
Gelesis Announces Initiation of a Six-Month Weight Loss Study with Gelesis100
January 09, 2015
Gelesis Presents Additional Clinical Data at the Obesity Society Annual Meeting
November 03, 2014
Gelesis Presents Results of Proof of Concept Weight Loss Study
June 23, 2014
Gelesis Expands Team to Advance Further Clinical Development of its Novel Obesity & Diabetes Therapy & Discloses Recent $12M Funding
May 16, 2014
Obesity Clinician, Arne Astrup, former President of the International Association for the Study of Obesity, joins Gelesis Advisory Board
March 01, 2013
Gelesis Presents New Data at The Obesity Society Annual Meeting
October 03, 2011
Gelesis Presents Mechanistic Data Supporting its Novel Clinical Stage Obesity Treatment at Obesity 2010
October 11, 2010

© 2021 Gelesis – All rights  reserved
Terms and conditions
Privacy Policy

E.U. GDPR – English | Italian
Social Media Community Guidelines
Patent Notice
Contact